@prefix this: <http://purl.org/np/RAwlUKOkdB0hlnEFIKDZZnj3Llnpi16vL85c7lnRd7t4w> .
@prefix sub: <http://purl.org/np/RAwlUKOkdB0hlnEFIKDZZnj3Llnpi16vL85c7lnRd7t4w#> .
@prefix drugbank: <http://identifiers.org/drugbank/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix mondo: <http://purl.obolibrary.org/obo/MONDO_> .
@prefix pav: <http://purl.org/pav/> .
@prefix infores: <https://w3id.org/biolink/infores/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix ntemplate: <https://w3id.org/np/o/ntemplate/> .
@prefix orcid: <https://orcid.org/> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix pmid: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix ncit: <http://purl.obolibrary.org/obo/NCIT_> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

<http://purl.org/np/RAwlUKOkdB0hlnEFIKDZZnj3Llnpi16vL85c7lnRd7t4w> a np:Nanopublication;
  np:hasAssertion sub:assertion;
  np:hasProvenance sub:provenance;
  np:hasPublicationInfo sub:pubInfo;
  prov:generatedAtTime "2022-09-16T11:53:46.825298"^^xsd:dateTime;
  prov:wasAttributedTo orcid:0000-0002-1501-1082;
  ntemplate:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .

drugbank:DB01175 a biolink:Drug;
  rdfs:label "escitalopram";
  biolink:category biolink:Drug .

<http://purl.obolibrary.org/obo/MONDO_0008114> a biolink:Disease;
  rdfs:label "obsessive-compulsive disorder";
  biolink:category biolink:Disease .

sub:association a biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
  rdf:object <http://purl.obolibrary.org/obo/MONDO_0008114>;
  rdf:predicate biolink:treats;
  rdf:subject drugbank:DB01175;
  rdfs:label "Escitalopram showed favorable pharmacokinetics and good tolerability. It is the most 5-HT-selective among SSRIs, with little or no affinity for other transmitter transporters or receptors [59]. Compared to other SSRIs, escitalopram may have weak or minimal interactions with the cytochrome P450 system [60, 61]. In a randomized, double-blind, placebo-controlled 24-week trial in OCD, escitalopram (20 mg/day) was associated with an increase in response rate compared to placebo after 12 weeks. Other placebo-controlled studies consistently showed escitalopram-related treatment response [25, 30]. 20 mg/day escitalopram has also been associated with better OCD symptom remission compared to 40 mg/day paroxetine or placebo at week 12 [30]. Three different escitalopram dosages (5, 10, and 20 mg/day) were compared with a fixed, 20 mg/day dose of paroxetine in a 12-week study, in which escitalopram showed both greater efficacy and better tolerability [62].";
  biolink:aggregator_knowledge_source infores:knowledge-collaboratory;
  biolink:category biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
  biolink:has_population_context sub:context;
  biolink:publications pmid:30101713;
  biolink:relation <http://purl.obolibrary.org/obo/NCIT_C94303> .

sub:context a biolink:Cohort;
  rdfs:label "adults";
  biolink:category biolink:Cohort .

sub:assertion prov:wasAttributedTo orcid:0000-0002-7641-6446 .

sub:sig npx:hasAlgorithm "RSA";
  npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCR9fz0fKCdWOWC+pxhkQhEM/ppbdIYe5TLSdj+lJzSlv9mYBaPgrzVezSwwbmhlHBPDZa4/vHycU315BdmUGq+pXllp9+rWFfrb+kBJwhZjpG6BeyyXBsRFz4jmQVxl/ZYHilQTh/XalYzKkEAyTiEMPee4Kz61PaWOKH24CsnOQIDAQAB";
  npx:hasSignature "PVsL+yEE5Nsi+zVQtMT5N+DrHb4vbNHsbuhBPors+w1mbZIGCe7HmtvoJ3RQm4aUMwU14uisPy1PiKff49zxkKra6uoWE0biyS7WmZGj3Cr7gTPVKo+ebWAVKzy7F4rinpYucZOqDamc811jGl8vbOlH8vR6sqL5rnFYZYT/Glk=";
  npx:hasSignatureTarget <http://purl.org/np/RAwlUKOkdB0hlnEFIKDZZnj3Llnpi16vL85c7lnRd7t4w> .

<https://w3id.org/biolink/vocab/> pav:version "2.3.0" .